- Home
- ZH vs GOSS Comparison
ZH vs GOSS Comparison
Compare ZH & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- GOSS
- Stock Information
- Founded
- ZH 2011
- GOSS 2015
- Country
- ZH China
- GOSS United States
- Employees
- ZH N/A
- GOSS N/A
- Industry
- ZH Business Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- GOSS Health Care
- Exchange
- ZH Nasdaq
- GOSS Nasdaq
- Market Cap
- ZH 365.1M
- GOSS 347.8M
- IPO Year
- ZH 2021
- GOSS 2019
- Fundamental
- Price
- ZH $4.81
- GOSS $2.47
- Analyst Decision
- ZH Strong Buy
- GOSS Strong Buy
- Analyst Count
- ZH 1
- GOSS 4
- Target Price
- ZH $4.70
- GOSS $8.50
- AVG Volume (30 Days)
- ZH 390.5K
- GOSS 3.1M
- Earning Date
- ZH 08-27-2025
- GOSS 08-05-2025
- Dividend Yield
- ZH N/A
- GOSS N/A
- EPS Growth
- ZH N/A
- GOSS N/A
- EPS
- ZH 0.22
- GOSS N/A
- Revenue
- ZH $439,821,184.00
- GOSS $40,237,000.00
- Revenue This Year
- ZH N/A
- GOSS N/A
- Revenue Next Year
- ZH $7.46
- GOSS $30.65
- P/E Ratio
- ZH $21.62
- GOSS N/A
- Revenue Growth
- ZH N/A
- GOSS N/A
- 52 Week Low
- ZH $3.13
- GOSS $0.66
- 52 Week High
- ZH $6.32
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- ZH 56.37
- GOSS 68.08
- Support Level
- ZH $4.58
- GOSS $2.38
- Resistance Level
- ZH $5.01
- GOSS $2.65
- Average True Range (ATR)
- ZH 0.28
- GOSS 0.15
- MACD
- ZH 0.02
- GOSS 0.03
- Stochastic Oscillator
- ZH 55.91
- GOSS 76.67
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.